Therapeutic Response Statement (Sensitivity)
This therapeutic response statement supports the relationship that dMMR status confers therapeutic sensitivity to Carboplatin, Dostarlimab, Paclitaxel in patients with Endometrial Carcinoma.
The European Medicines Agency (EMA) has authorized dostarlimab in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR) / microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (EC) who are candidates for systemic therapy.
This statement is based on a regulatory approval from the European Medicines Agency:
JEMPERLI is indicated in combination with carboplatin and paclitaxel for the treatment of adult patients with mismatch repair deficient (dMMR)/ microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer (EC) and who are candidates for systemic therapy.